A landmark CRISPR breakthrough from ChristianaCare’s Gene Editing Institute has overturned chemotherapy resistance in lung squamous cell carcinoma, restoring drug sensitivity by surgically excising the NRF2 gene—a master regulator of cellular stress that shields tumors from cytotoxic assaults. In rigorous in vitro and in vivo studies, CRISPR/Cas9 precisely knocked out NRF2 in cells harboring the R34G mutation, reinstating vulnerability to staples like carboplatin and paclitaxel. Even partial editing (20-40% of cells) curbed tumor growth by 50% in mouse models, underscoring the technique’s potency in heterogeneous cancers.
Lung cancer, claiming over 190,000 U.S. diagnoses annually, often evades treatment via NRF2 hyperactivation, which upregulates antioxidants and efflux pumps to expel drugs. This targeted edit disrupts that armor, slowing proliferation and enhancing apoptosis without broad genomic collateral. Extending beyond lungs, NRF2 drives resistance in liver, esophageal, and head/neck tumors, suggesting a versatile combinatorial therapy. While delivery challenges like viral vectors persist, non-viral lipid nanoparticles show promise for clinical translation. This feat exemplifies CRISPR‘s evolution from lab curiosity to therapeutic powerhouse, potentially extending survival in refractory cases and inspiring multiplexed edits for polygenic resistances.
